The earnings call presented a mixed picture. Significant growth in Fanapt revenue and prescriptions, as well as promising regulatory advancements for Bysanti, were overshadowed by increased net losses, declining HETLIOZ and PONVORY revenues, and higher operating expenses. While there are strong strategic developments, financial challenges remain significant.

Company Guidance

During the Q2 2025 earnings call, Vanda Pharmaceuticals provided guidance for the fiscal year, projecting total revenue from its commercial products Fanapt, HETLIOZ, and PONVORY to be between $210 million and $250 million, reflecting a potential growth of 6% to 26% compared to 2024. Year-end cash is expected to range from $280 million to $320 million. The company highlighted the successful expansion of the Fanapt sales force, with a 27% increase in Fanapt revenue due to the launch of its bipolar I indication. Fanapt's total prescriptions increased by approximately 24% year-over-year. Vanda is also preparing for the potential launch of Bysanti, which could be commercially available by Q3 2026, assuming timely FDA approval. The company emphasized continued investments in its sales and marketing infrastructure to support its growth strategy, especially focusing on increasing awareness for its products across the U.S.

Fanapt Revenue Growth

Fanapt revenue increased by 27% compared to the same period in the prior year, driven by the launch of the bipolar I indication.

Expansion of Fanapt Sales Force

Vanda expanded its sales force, resulting in a 40% increase in activity compared to Q1 2025 and over 400% compared to Q2 2024.

Strong Prescription Growth for Fanapt

Fanapt new-to-brand prescriptions increased by over 200% compared to the second quarter of 2024 and by over 50% compared to the first quarter of 2025.

Regulatory Advances for Bysanti

The NDA for Bysanti for bipolar I disorder and schizophrenia was accepted for filing by the FDA with exclusivity potentially extending into the 2040s.

PONVORY New Patient Growth

PONVORY new patient prescriptions in the second quarter of 2025 grew to a record high since the initiation of Vanda's commercial launch.

Vanda (VNDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VNDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.43 / -	-0.09	―	―	―
Jul 31, 2025	2025 (Q2)	-0.36 / -0.46	-0.08	-475.00% (-0.38)	―
May 07, 2025	2025 (Q1)	-0.57 / -0.50	-0.07	-614.29% (-0.43)	―
Feb 13, 2025	2024 (Q4)	-0.11 / -0.08	-0.04	-100.00% (-0.04)	―
Nov 06, 2024	2024 (Q3)	-0.16 / -0.09	0	―	―
Jul 31, 2024	2024 (Q2)	-0.19 / -0.08	0.03	-366.67% (-0.11)	―
May 08, 2024	2024 (Q1)	0.05 / -0.07	0.06	-216.67% (-0.13)	―
Feb 07, 2024	2023 (Q4)	-0.09 / -0.04	0.12	-133.33% (-0.16)	―
Nov 08, 2023	2023 (Q3)	-0.04 / 0.00	0.06	―	―
Jul 27, 2023	2023 (Q2)	-0.13 / 0.03	0.05	-40.00% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VNDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$4.67	$4.26	-8.78%
May 07, 2025	$4.38	$4.22	-3.65%
Feb 13, 2025	$4.70	$4.42	-5.96%
Nov 06, 2024	$4.89	$5.02	+2.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vanda Pharmaceuticals Inc. (VNDA) report earnings?

Vanda Pharmaceuticals Inc. (VNDA) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Vanda Pharmaceuticals Inc. (VNDA) earnings time?

Vanda Pharmaceuticals Inc. (VNDA) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VNDA EPS forecast?

VNDA EPS forecast for the fiscal quarter 2025 (Q3) is -0.43.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing